Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02376868 · ClinicalTrials.gov registry record
Maestro Agreement and Precision Study II
A clinical trial, sponsored by Topcon Medical Systems.
- Completed
- Registry status
- 101
- Enrollment target
NCT02376868: Completed study, sponsored by Topcon Medical Systems.
NCT02376868 is a clinical trial that has completed, run by Topcon Medical Systems. The registered enrollment target is 101 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02376868 has completed, sponsored by Topcon Medical Systems.
- COMPLETED
- Registry status
- 101 participants
- Enrollment target
Study Summary
Assess the repeatability and agreement of the Optic Disc Parameters, Retinal Nerve Fiber Layer (RNFL) Thickness, Full Retinal Thickness, and Ganglion Cell Thickness between the Maestro and iVue OCT devices.
Interventions
- DEVICE 3D OCT-1 Maestro
- DEVICE iVue
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2015-05 |
| Est. Completion | 2015-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02376868
The ClinicalTrials.gov registry entry for NCT02376868 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Topcon Medical Systems, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 3D OCT-1 Maestro is the first listed.
NCT02376868 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02376868 about?
NCT02376868 is a clinical study titled "Maestro Agreement and Precision Study II". Assess the repeatability and agreement of the Optic Disc Parameters, Retinal Nerve Fiber Layer (RNFL) Thickness, Full Retinal Thickness, and Ganglion Cell Thickness between the Maestro and iVue OCT devices.
What is the current status of trial NCT02376868?
This trial is currently completed. The enrollment target is 101 participants. The study started on 2015-05. Estimated completion is 2015-09.
What interventions are being tested in trial NCT02376868?
The interventions under investigation include: 3D OCT-1 Maestro (DEVICE), iVue (DEVICE).
Who is sponsoring clinical trial NCT02376868?
This trial is sponsored by Topcon Medical Systems, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.